Amygdala Neuroscience
Amygdala Neurosciences is developing ANS-6637 a new chemical entity with a novel MOA for treating substance use disorder. Based on a mechanism of action in the brain (published in Nature Medicine) that prevents pathophysiologic dopamine surge without changes to basal dopamine, ANS-6637 has the potential to prevent drug seeking behavior, craving and relapse. In pre-clinical studies, ALDH2 inhibition reduced self-administration, cue- and drug-primed relapse in nicotine, alcohol, cocaine, heroin, methamphetamine and binge eating models and also demonstrated anxiolytic properties in models of stress. ANS-6637 has completed extensive Phase 1 studies and is ready for Phase 2 efficacy studies. Their initial development focus is for smoking cessation with parallel development efforts for cocaine, opioid and alcohol use disorders.
Tech Stack (17 technologies)
Frequently Asked Questions
What technologies does Amygdala Neuroscience use?+
Amygdala Neuroscience uses 17 technologies including Google Analytics, Google Tag Manager, MDBootstrap.
What industry is Amygdala Neuroscience in?+
Amygdala Neuroscience operates in the Addiction Treatment industry.
Where is Amygdala Neuroscience based?+
Amygdala Neuroscience is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026